InspireMD, Inc. — Director's Dealing 2023

May 16, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: InspireMD, Inc. (NSPR)
CIK: 0001433607
Period of Report: 2023-05-12

Reporting Person: Kester Thomas J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-12	Common Stock	P	61249	$1.6327	Acquired	108590	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-12	Series H Warrants to purchase Common Stock	$1.3827	P	30625	Acquired		Common Stock (30625)	Direct
2023-05-12	Series I Warrants to purchase Common Stock	$1.3827	P	30624	Acquired		Common Stock (30624)	Direct
2023-05-12	Series J Warrants to purchase Common Stock	$1.3827	P	30625	Acquired		Common Stock (30625)	Direct
2023-05-12	Series K Warrants to purchase Common Stock	$1.3827	P	30624	Acquired		Common Stock (30624)	Direct

Footnotes

F1: The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").

F2: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F3: The aggregate number of warrants reported in this row consists of 30,625 Series H Warrants that were acquired in the Private Placement.

F4: The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial.

F5: The aggregate number of warrants reported in this row consists of 30,624 Series I Warrants that were acquired in the Private Placement.

F6: The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm).

F7: The aggregate number of warrants reported in this row consists of 30,625 Series J Warrants that were acquired in the Private Placement.

F8: The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm.

F9: The aggregate number of warrants reported in this row consists of 30,624 Series K Warrants that were acquired in the Private Placement.

F10: The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin.